drupal statistics module

Jump to content


hair loss radio

Bill

Member Since 08 Jan 2006
Offline Last Active Nov 10 2017 03:08 PM
-----

Topics I've Started

Ds Healthcare Group Prepares To File Investigational New Drug Application With Fda For...

11 January 2014 - 04:39 AM

Move follows recent patent application for topical prescription-grade treatment.

 

ds-logo.gif

 

DS Healthcare Group, Inc, a leading developer of personal care products, today announced it is preparing to submit to the United States Food and Drug Administration (FDA) an Investigational New Drug Application (IND) for its proprietary topical hair loss treatment.

 

On October 29, 2013 the Company had announced it filed a patent with the United States Patent and Trademark Office for the invention.

 

An IND is a request for the FDA's authorization to administer an investigational drug to humans and is the first step towards designing and conducting clinical trials in the U.S.

 

DS Healthcare is currently in late stage discussions with various clinical research organizations (CROs) to design and conduct clinical trials for its breakthrough hair loss treatment.

 

"The highly lucrative prescription market for hair loss treatments currently does not serve the needs of many patients. Regulatory approval, plus our patent-pending technology would expand our leadership position in hair loss therapies," stated DS Healthcare President and CEO Daniel Khesin.

 

Full article


Propecia Peyronie’S Disease Lawsuit Filed

05 January 2014 - 03:17 PM

A Propecia Peyronie’s disease lawsuit has been filed against Merck & Co, Inc. by a Madison County, AL husband and wife.

 

Propecia-head.jpg

 

The plaintiffs claim thatMerck either knew, or should have known, that hair loss drug Propecia can cause serious side effects when used as intended, including cognitive impairment, sexual dysfunction and depression. 

 

The plaintiffs seek compensatory and special damages form Merck, as well as punitive damages because Merck allegedly demonstrated reckless indifference to the health and well-being of the public.

 

The lawsuit claims that the plaintiff suffered cognitive impairment, as well as severe sexual dysfunction and Peyronie’s disease after taking Propecia to treat male pattern hair loss.  

 

The plaintiffs allege that these side effects continued after the use of Propecia was discontinued and that both husband and wife are experiencing ongoing losses including diminished quality of life and a loss of their sexual relationship.

 

Complete article


Hair Transplant Center Announces Recruiting Hair Loss Patients For A Multi-Central Fue...

04 January 2014 - 08:11 AM

Founder of US Hair Restoration and the Chair of FUE Research Committee, Dr. Parsa Mohebi is conducting a new study to compare FUE vs strip method. 
 

Before-and-After-Hair-Transplant.png

The FUE Research Committee of the International Society of Hair Restoration was established to research the differences between the two common methods of hair restoration, FUE and strip method.


One of the goals of the FUE Research Committee is to optimize the quality of FUE hair transplantation.


The newest multi-center study being conducted by the FUE Research Committee is the FUE vs strip hair transplant study.


This one of a kind study will compare results observed from both methods of hair restoration, (follicular unit extraction and strip method) providing evidence as to which method is more successful when comparing hair survival, quality, thickness, and overall hair characteristics.


Dr. Parsa Mohebi, chairman of the FUE Research committee states that the goal of this study is to answer many basic questions,


“Whether or not doing FUE affects the quality of hair transplants? How the quality of hair compares with traditional methods of strip hair transplant and what are the long term differences between the two methods? Once these questions have been answered we can further study the advanced methods to improve the quality of FUE Transplants.”

 

Full article


Body Hair Transplant With Ugraft Now Allows Hair Restoration For The Severely Bald

03 January 2014 - 06:47 AM

Hair loss, thinning and balding is a major concern for men in America that prompts many to seek hair loss treatments. 
 

body-hair-transplant-ugraft.jpg


Due to the lack of hair restoration options for the severely bald and a desire to help men with failed prior hair transplant surgeries, Dr. Sanusi Umar of DermHair Clinic created the uGraft technique, also known as the Umar Procedure.


Since a full head of thick hair represents youth and vitality in our society, men who experience hair loss can experience negative self-esteem and decreased self-confidence.


While many men opt for surgical hair restoration, those with severe hair loss and balding are sometimes problematic cases in terms of traditional hair transplants.


Men who are severely bald are typically not candidates for hair transplantation due to lack of traditional donor hair on the head.

Others with botched past hair transplants also lack options due to inadequate traditional donor source of hair from the back and sides of the scalp.


Some men simply need an additional hair transplant if they got one early in life and then suffered additional extreme hair loss.

 

Full article

 

 


Ds Healthcare Group To Launch Oral Tablet In Multi-Billion-Dollar Hair-Loss Market

07 December 2013 - 02:02 AM

DS Healthcare Group Inc. a leading developer of personal care products, announced that it has developed and will launch an over-the-counter neutraceutical tablet to combat premature hair thinning and improve healthy hair growth.

 

ds-logo.gif
 

Sold under the DS Laboratories brand, the tablet will complement and extend the company's industry-leading topical treatments, which promote longer, stronger, thicker hair.

 

The new DS Laboratories tablet will launch in Mexico during the first quarter of 2014. It will expand worldwide through the company's growing network of foreign markets.

 

DS Laboratories products already sell in more than 15 countries as part of a rapid global expansion.

 

The new oral supplement employs a novel approach within the thinning-hair category -- complex peptides with potent antioxidants -- to maximize efficacy and potency. This formula results from ongoing clinical research at DS Healthcare Group on hair loss and related conditions.

 

"We've developed our own proprietary tablet, which contains a unique composition of ingredients, to achieve a real breakthrough in neutraceutical research," stated DS Healthcare President and CEO Daniel Khesin.

 

Full article